In a move that appears to prioritize biomedical engineering over cancer research, President Joe Biden’s proposal for fiscal year 2023 cuts NCI funding by $199 million, a 2.9% percent cut from the current year’s level.
Worry not, because support for cancer research remains strong, NCI Director Ned Sharpless said, even as the institute stalls in its attempts to increase paylines in fiscal year 2022 and as the White House requests a nearly $200 million cutto the FY23 NCI budget.
The FY22 spending bill increases NCI’s budget by $159 million—but according to NCI officials, this boost isn’t sufficient to raise paylines for R01 grants for established and new investigators.
In support of the reignited Cancer Moonshot’s goal of fostering data sharing in cancer research, the National Cancer Institute has launched the Molecular Characterization Initiative for pediatric tumors (The Cancer Letter, Feb. 4, 2022).
Changes at Mission Control notwithstanding, the new Cancer Moonshot is ready for liftoff, says Danielle Carnival, coordinator of the White House cancer initiative.
President Joe Biden’s new national goal for the reignited Cancer Moonshot—to cut today’s age-adjusted cancer mortality rates by at least 50% before 2050—is bold, but achievable, said NCI Director Ned Sharpless.
NCI has issued a Request for Information seeking input from developers of multi-cancer early detection liquid biopsy tests, with the goal of launching an NCI-sponsored randomized controlled screening clinical trial of these tools.
Fifty years ago, the National Cancer Act was signed into law, providing the National Cancer Institute with new authority to expand discoveries in basic, clinical, and translational science, which included building a nationwide network of cancer centers to treat thousands of patients each day.
The NCI Board of Scientific Advisors approved 11 new and reissued concepts at a joint meeting of the BSA and the National Cancer Advisory Board Dec. 7-9.
To accurately gauge the impact of the National Cancer Act of 1971 at the half-century point, Abbe R. Gluck and Charles S. Fuchs decided to focus on more than the science of cancer.